Measurable outcomes in psychiatric disorders: Remission as a marker of wellness

Clinical Therapeutics

Volumn 28, Issue 11, 2006, Pages 1882-1891

  McIntyre, Roger S ^a   Fallu, Angelo ^b   Konarski, Jakub Z ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

anxiety disorders; attention deficit hyperactivity disorder; bipolar disorder; depression; patient outcomes; remission; wellness

Indexed keywords

ANTIDEPRESSANT AGENT; DEXAMETHASONE;

ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; DEPRESSION; HAMILTON SCALE; HUMAN; MEDLINE; MENTAL DISEASE; MENTAL HEALTH; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; RATING SCALE; REMISSION; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT PLANNING; VALIDATION PROCESS; WELLBEING;

BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MENTAL DISORDERS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 33845979893     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.11.007     Document Type: Article

References (65)

1. Available at:. Health Canada [Web site]. A report on mental illnesses in Canada. Accessed March 10, 2003 (2002), Health Canada, Ottawa, Canada. http://www.apheo.ca/indicators/pages/resources/data%20sources/canadianco mmunityhealthsurvey.htm
2. (PMID: 15748042). Wilkins K. Bipolar/Disorder, Social Support and Work. Health Reports (2004), Statistics Canada, Ottawa, Canada 21-30
3. Narrow W.E., Rae D.S., Robins L.N., and Regier D.A. Revised prevalence estimates of mental disorders in the United States: Using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 59 (2002) 115-123
4. Weissman M.M., Bland R.C., Canino G.J., et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 276 (1996) 293-299
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (1994), American Psychiatric Association, Washington, DC
6. Kessler R.C., McGonagle K.A., Zhao S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51 (1994) 8-19
7. Brown R.T., Freeman W.S., Perrin J.M., et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 107 (2001) E43
8. Burd L., Klug M.G., Coumbe M.J., and Kerbeshian J. Children and adolescents with attention deficit-hyperactivity disorder: 1. Prevalence and cost of care. J Child Neurol. 18 (2003) 555-561
9. Barbaresi W., Katusic S., Colligan R., et al. How common is attention-deficit/hyperactivity disorder? Towards resolution of the controversy: Results from a population-based study. Acta Paediatr Suppl. 93 (2004) 55-59
10. Demyttenaere K., Bruffaerts R., Posada-Villa J., et al., WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 291 (2004) 2581-2590
11. Krishnan K.R. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 67 (2005) 1-8
12. Murray C., and Lopez A. The Global Burden of Disease. World Health Organization (1996), Harvard University Press, Cambridge, Mass
13. Hirschfeld R.M., Keller M.B., Panico S., et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 277 (1997) 333-340
14. Keller M.B. Remission versus response: The new gold standard of antidepressant care. J Clin Psychiatry 65 Suppl 4 (2004) 53-59
15. Keller M.B. Past, present, and future directions for defining optimal treatment outcome in depression: Remission and beyond. JAMA 289 (2003) 3152-3160
16. Paykel E.S., Ramana R., Cooper Z., et al. Residual symptoms after partial remission: An important outcome in depression. Psychol Med. 25 (1995) 1171-1180
17. Arborelius L., Owens M.J., Plotsky P.M., and Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 160 (1999) 1-12
18. Musselman D.L., Betan E., Larsen H., and Phillips L.S. Relationship of depression to diabetes types 1 and 2: Epidemiology, biology, and treatment. Biol Psychiatry 54 (2003) 317-329
19. Holthoff V.A., Beuthien-Baumann B., Zundorf G., et al. Changes in brain metabolism associated with remission in unipolar major depression. Acta Psychiatr Scand. 110 (2004) 184-194
20. McIntyre R.S., Konarski J.Z., Mancini D.A., et al. Measuring the severity of depression and remission in primary care: Validation of the HAMD-7 scale [published correction ap pears in CMAJ. 2006;174:207]. CMAJ 173 (2005) 1327-1334
21. Frank E., Prien R.F., Jarrett R.B., et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48 (1991) 851-855
22. Judd L.L., Akiskal H.S., Zeller P.J., et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 57 (2000) 375-380
23. Judd L.L., Paulus M.J., Schettler P.J., et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?. Am J Psychiatry 157 (2000) 1501-1504
24. Judd L.L., Akiskal H.S., Maser J.D., et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55 (1998) 694-700
25. Brown E.S., Varghese F.P., and McEwen B.S. Association of depression with medical illness: Does cortisol play a role?. Biol Psychiatry 55 (2004) 1-9
26. Paykel E.S. Remission and residual symptomatology in major depression. Psychopathology 31 (1998) 5-14
27. Miller I.W., Keitner G.I., Schatzberg A.F., et al. The treatment of chronic depression, part 3: Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 59 (1998) 608-619
28. Judd L.L., Akiskal H.S., Maser J.D., et al. Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 50 (1998) 97-108
29. Lin E.H., Katon W.J., Von Korff M., et al. Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med. 7 (1998) 443-449
30. Thase M.E., Simons A.D., McGeary J., et al. Relapse after cognitive behavior therapy of depression: Potential implications for longer courses of treatment. Am J Psychiatry 149 (1992) 1046-1052
31. Bula C., Wietlisbach V., Burnand B., and Yersin B. Depressive symptoms as a predictor of 6-month outcomes and services utilization in elderly medical inpatients. Arch Intern Med. 161 (2001) 2609-2615
32. Lee Y., Choi K., and Lee Y.K. Association of comorbidity with depressive symptoms in community-dwelling older persons. Gerontology 47 (2001) 254-262
33. Pouget R., Yersin B., Wietlisbach V., et al. Depressed mood in a cohort of elderly medical inpatients: Prevalence, clinical correlates and recognition rate. Aging (Milano) 12 (2000) 301-307
34. Kessler R.C., Borges G., and Walters E.E. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry 56 (1999) 617-626
35. Unutzer J., Patrick D.L., Simon G., et al. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older. A 4-year prospective study. JAMA 277 (1997) 1618-1623
36. Simon G., Ormel J., Von Korff M., and Barlow W. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 152 (1995) 352-357
37. Tranter R., O'Donovan C., Chandarana P., and Kennedy S. Prevalence and outcome of partial remission in de pression. J Psychiatry Neurosci. 27 (2002) 241-247
38. Doraiswamy P.M., Khan Z.M., Donahue R.M., and Richard N.E. Quality of life in geriatric depression: A compari son of remitters, partial responders, and nonresponders. Am J Geriatr Psychiatry 9 (2001) 423-428
39. Simon G.E., VonKorff M., Piccinelli M., et al. An international study of the relation between somatic symptoms and depression. N Engl J Med. 341 (1999) 1329-1335
40. Simon G.E., VonKorff M., and Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry 52 (1995) 850-856
41. Katon W., and Schulberg H. Epidemiology of depression in primary care. Gen Hosp Psychiatry 14 (1992) 237-247
42. Simon G.E., Revicki D., Heiligenstein J., et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 22 (2000) 153-162
43. Druss B., Schlesinger M., and Allen Jr. H.M. Depressive symptoms, satisfaction with health care, and 2-year work outcomes in an employed population. Am J Psychiatry 158 (2001) 731-734
44. Frank E., Kupfer D.J., Perel J.M., et al. Comparison of full-dose versus halfdose pharmacotherapy in the main tenance treatment of recurrent depression. J Affect Disord. 27 (1993) 139-145
45. Judd L.L., Schettler P.J., Akiskal H.S., et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol. 6 (2003) 127-137
46. Keller M.B., Lavori P.W., Kane J.M., et al. Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. Arch Gen Psychiatry 49 (1992) 371-376
47. Young R.C., Biggs J.T., Ziegler V.E., and Meyer D.A. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 133 (1978) 429-435
48. Tohen M., Jacobs T.G., Grundy S.L., et al., Olanzapine HGGW Study Group. Efficacy of olanzapine in acute bipolar mania: A doubleblind, placebo-controlled study [published correction appears in Arch Gen Psychiatry. 2002;59:911. Arch Gen Psychiatry 57 (2000) 841-849
49. Chengappa K.N., Baker R.W., Shao L., et al. Rates of response, euthymia and remission in two placebo controlled olanzapine trials for bipolar mania. Bipolar Disord. 5 (2003) 1-5
50. McIntyre R.S., Konarski J.Z., and Yatham L.N. Comorbidity in bipolar disorder: A framework for rational treatment selection. Hum Paychopharmacol. 19 (2004) 369-386
51. Kennedy N., Boydell J., Kalidindi S., et al. Gender differences in incidence and age at onset of mania and bipo lar disorder over a 35-year period in Camberwell, England. Am J Psychiatry 162 (2005) 257-262
52. Andreasen N.C., Carpenter Jr. W.T., Kane J.M., et al. Remission in schizophrenia: Proposed criteria and ra tionale for consensus. Am J Psychiatry 162 (2005) 441-449
53. Kessler R. Comorbidity of unipolar and bipolar depression with other psychiatric disorders in a general population survey. In: Tohen M. (Ed). Comorbidity in Affective Disorders (1999), Marcel Dekker, Inc, New York, NY 1-25
54. McElroy S.L., Altshuler L.L., Suppes T., et al. Axis I psychiatric comorbidity and its relationship to historical ill ness variables in 288 patients with bipolar disorder. Am J Psychiatry 1158 (2001) 420-426
55. Ballenger J.C. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 60 Suppl 22 (1999) 29-34
56. Leon A.C., Shear M.K., Portera L., and Klerman G.L. Assessing impairment in patients with panic disorder: The Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol. 27 (1992) 78-82
57. Ballenger J.C. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry 65 (2004) 1696-1707
58. Stein M.B., Pollack M.H., Bystritsky A., et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial. Psychopharmacology (Berl) 177 (2005) 280-288
59. Antony M. Measures for specific phobia. In: Antony M., Orsillo S., and Roemer L. (Eds). Practitioner's Guide to Empirically-Based Measures of Anxiety (2001), Kluwer Academic Publishers, New York, NY 133-158
60. Gorwood P. Generalized anxiety disorder and major depressive disorder comorbidity: An example of genetic pleiotropy?. Eur Psychiatry 19 (2004) 27-33
61. Swanson J.M., Kraemer H.C., Hinshaw S.P., et al. Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40 (2001) 168-179
62. Washington, DC. Abstract NR483. Steele M., Riccardelli R., and Binder C. Effectiveness of Concerta versus usual care methylphenidate immediate release in children with ADHD. Presented at: New Research Abstracts, Annual Meeting of the American Psychiatric Association (May 1-6, 2004)
63. Stein M.A., Sarampote C.S., Waldman I.D., et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 112 (2003) e404
64. Michelson D., Allen A.J., Busner J., et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebocontrolled study. Am J Psychiatry 159 (2002) 1896-1901
65. Kelsey D.K., Sumner C.R., Casat C.D., et al. Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebocontrolled trial. Pediatrics 114 (2004) e1-e8